Join Glenn Hunzinger and James Woods as they discuss what to expect for medtech dealmaking in 2026, including why buyers are poised to return, how technology is reshaping portfolios, and where investors are focusing to drive future growth.

Discussion highlights:

• Medtech M&A is expected to rebound in 2026 as market conditions improve and capital remains available
• Buyers are staying selective, prioritizing assets that support durable growth
• Technology and data enabled solutions are key drivers of deal activity
• Tuck in and bolt on acquisitions continue to dominate, with private equity playing an active role
• Surgical robotics, AI, cardiovascular, and diagnostics remain areas of strong interest

Speakers:
Glenn Hunzinger, US Health Industries Leader, PwC
James Woods, US Medtech Deals Leader, PwC

Linked materials:

• https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html
• https://www.pwc.com/us/en/industries/health-industries/library/medtech-deals-outlook.html
• https://www.pwc.com/us/en/industries/health-industries/library/health-services-deals-outlook.html

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.